Wellington Management Group
PSTX

Wellington Management Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Wellington Management Group’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-339,715
Closed -$3.26M – 2080
2024
Q4 		$3.26M Buy
339,715
+31,352
+10% +$164K ﹤0.01% 1457
2024
Q3 		$882K Sell
308,363
-78,968
-20% -$244K ﹤0.01% 1736
2024
Q2 		$1.13M Buy
387,331
+30,435
+9% +$83.2K ﹤0.01% 1650
2024
Q1 		$1.14M Buy
+356,896
New +$1.19M ﹤0.01% 1659
2023
Q2 		– Sell
-372,285
Closed -$1.15M – 2046
2023
Q1 		$1.15M Sell
372,285
-1,400,211
-79% -$8.39M ﹤0.01% 1620
2022
Q4 		$9.39M Buy
1,772,496
+577,716
+48% +$2.64M ﹤0.01% 1106
2022
Q3 		$4.22M Buy
+1,194,780
New +$3.95M ﹤0.01% 1330

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wellington Management Group's PSTX Position: Q1 2025 in Review

Wellington Management Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 339,715 shares — an estimated $3.26M sold.

Wellington Management Group first reported a position in PSTX in Q3 2022 and held it in 7 quarters. The position peaked at $9.39M in Q4 2022. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Wellington Management Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Wellington Management Group sold 339,715 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $3.26M.
  • Wellington Management Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 7 quarters.
  • Wellington Management Group's Poseida Therapeutics, Inc. Common Stock position peaked at $9.39M in Q4 2022.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Wellington Management Group's 13F filing for Q1 2025, filed 13 May 2025.